Product Description
Sargramostim, granulocyte-macrophage colony-stimulating factor, a hematopoietic growth factor, stimulates cells of the intestinal innate immune system. Preliminary studies suggest sargramostim may have activity in Crohn's disease (Sourced from: https://pubmed.ncbi.nlm.nih.gov/15917384/)
Mechanisms of Action: GM-CSF Inhibitor
Novel Mechanism: No
Modality: Coagulation Factor
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Greece | India | Ireland | Peru | Portugal | Slovenia | Ukraine | United Kingdom | United States
Approved Indications: Acute Leukemia | Acute Myeloid Leukemia | Leukemia | Myeloid Leukemia | Bone Marrow Transplantation | Stem Cell Transplant | Acute Radiation Syndrome
Known Adverse Events: Hypertension | Abdominal Pain | Headache | Labor Pain | Pain Unspecified | Alopecia | Stomatitis | Skin Abnormalities | Acute Myeloid Leukemia | Hypertension, Pulmonary | Pulmonary Edema | Anorexia | Asthenia | Diarrhea | Edema | Weight Loss
Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Canada, United States
Active Clinical Trial Count: 3
Highest Development Phases
Phase 2: Alzheimer Disease
Phase 1: Parkinson's Disease|Parkinsonian Disorders|Respiratory Aspiration
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| SESAD | P2 |
Recruiting |
Alzheimer Disease |
2026-04-30 |
|
| 0748-22-FB | P1 |
Completed |
Parkinsonian Disorders|Parkinson's Disease |
2024-04-12 |
|
| PTX-001-005 | P1 |
Completed |
Respiratory Aspiration |
2022-05-27 |
28% |